Duloxetine for the Treatment of Fibromyalgia in Women: Pooled Results from Two Randomized, Placebo-Controlled Clinical Trials
- 1 October 2007
- journal article
- research article
- Published by SAGE Publications in Journal of Women's Health
- Vol. 16 (8) , 1145-1156
Abstract
Background: To assess the efficacy (in particular, in pain, functional impairment, and quality of life) and safety and tolerability (incidence of adverse events, discontinuation rates, changes in laboratory findings, and vital signs) of duloxetine in female patients with fibromyalgia. Methods: Data were pooled from two placebo-controlled clinical trials of similar design (randomized, 12-week, and double-blind), comparing duloxetine 60 mg a day (q.d.) or 60 mg twice daily (b.i.d.) (n = 326) with placebo (n = 212), in women who met the American College of Rheumatology criteria for primary fibromyalgia. Results: Compared with the patients receiving placebo, duloxetine-treated female patients demonstrated a significantly greater improvement in the Brief Pain Inventory (BPI) average pain severity score and in the Fibromyalgia Impact Questionnaire (FIQ) total score, beginning at week 1 and continuing through week 12 (p < 0.001). Duloxetine was superior to placebo on all efficacy measures, including mean tender point threshold, Clinical Global Impression of Severity, Patient Global Impression of Improvement, and average interference from pain scores. The duloxetine-treated group was superior to placebo on all quality of life and functional measures, including each domain of the Medical Outcomes Study Short Form-36 (SF-36). A direct treatment effect of duloxetine on pain reduction was demonstrated and shown to be independent of secondary improvement in mood (based on BPI average pain score). Significantly more duloxetine-treated patients reported treatment-emergent adverse events (296 [90.8%] duloxetine-treated and 165 [77.8%] placebo-treated, p < 0.001). Rates of serious adverse events were similar between duloxetine-treated and placebo-treated patients. Conclusions: The pooled results of these studies demonstrate that duloxetine is a safe and efficacious treatment for both the pain and functional impairment associated with fibromyalgia in female patients, while significantly improving quality of life.Keywords
This publication has 19 references indexed in Scilit:
- Duloxetine vs. placebo in patients with painful diabetic neuropathyPain, 2005
- Efficacy of Duloxetine, a Potent and Balanced Serotonin-Norepinephrine Reuptake Inhibitor in Persistent Pain Models in RatsThe Journal of Pharmacology and Experimental Therapeutics, 2004
- Effects of Duloxetine on Painful Physical Symptoms Associated With DepressionPsychosomatics, 2004
- Cerebrospinal fluid biogenic amine metabolites, plasma‐rich platelet serotonin and [3H]imipramine reuptake in the primary fibromyalgia syndromeRheumatology, 2001
- THE RELATIONSHIP BETWEEN FIBROMYALGIA AND MAJOR DEPRESSIVE DISORDERRheumatic Disease Clinics of North America, 1996
- The prevalence and characteristics of fibromyalgia in the general populationArthritis & Rheumatism, 1995
- The projections of noradrenergic neurons in the A5 catecholamine cell group to the spinal cord in the rat: anatomical evidence that A5 neurons modulate nociceptionBrain Research, 1993
- Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritisArthritis & Rheumatism, 1992
- The american college of rheumatology 1990 criteria for the classification of fibromyalgiaArthritis & Rheumatism, 1990
- Endogenous Pain Control Systems: Brainstem Spinal Pathways and Endorphin CircuitryAnnual Review of Neuroscience, 1984